2-Cyano-N-(4-(fluoromethyl)phenyl)-3-hydroxybut-2-enamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Cyano-N-(4-(fluoromethyl)phenyl)-3-hydroxybut-2-enamide
• 英文别名: (Z)-2-cyano-N-[4-(fluoromethyl)phenyl]-3-hydroxybut-2-enamide
• 化学式: C₁₂H₁₁FN₂O₂
• 分子量: 234.23
• InChiKey: HYUAOBRYSNIRDG-FLIBITNWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  73.1
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• (Z)-2-CYANO-3-HYDROXY-BUT-2-ENOIC ACID-(4'-TRIFLUORMETHYLPHENYL)-AMIDE TABLET FORMULATIONS WITH IMPROVED STABILITY
  申请人：SANOFI

  公开号：US20140235888A1

  公开（公告）日：2014-08-21

  The invention relates to solid pharmaceutical compositions comprising (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis.
• METHODS FOR REDUCING THE RISK OF AN ADVERSE TERIFLUNOMIDE AND ROSUVASTATIN INTERACTION IN MULTIPLE SCLEROSIS PATIENTS
  申请人：SANOFI

  公开号：US20160030427A1

  公开（公告）日：2016-02-04

  This invention relates to a method for managing the risk of an adverse interaction between teriflunomide and a substrate of breast cancer resistance protein (BCRP) and/or organic anion transporting polypeptide B1 and B3 (OATP1B1/B3).